Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index

Journal of Diabetes Investigation

Volumn 4, Issue 2, 2013, Pages 214-221

  Wu, Qianlin ^a   Xiao, Zhu ^a   Cheng, Zhong ^a   Tian, Haoming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Gastrointestinal hormones; Roux en Y gastric bypass; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; OXYNTOMODULIN; PEPTIDE YY;

ADULT; ARTICLE; BODY MASS; CHINESE; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; STOMACH BYPASS; UPREGULATION; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84878358794     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12005     Document Type: Article

References (25)

1. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev 2009; CD003641.
2. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
3. Joshua PT, David EC. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009; 150: 2518-2525.
4. O'Brien PE, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg 2006; 16: 1032-1040.
5. Higa KD, Ho T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. J Laparoendosc Adv Surg Tech A 2001; 11: 377-382.
6. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256.
7. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.
8. Michael AN. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124(1S): S3-S18.
9. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117: 24-32.
10. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
11. Meier JJ, Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2008; 4: 606-607.
12. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687.
13. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
14. Chinese Diabetes Society. China Guideline for Type 2 Diabetes. Chinese Diabetes Society, Beijing, 2010.
15. Cummings DE, Overduin J, Shannon MH, et al. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis 2005; 1: 358-368.
16. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709-1716.
17. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781-1789.
18. Vilsbøll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119.
19. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes. Diabetes 2009; 58: 1342-1349.
20. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287: E1209-E1215.
21. Laferrère B. Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009; Dec. 35(Pt 2): 513-517.
22. Sarah S, Katie W, Steve B. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol 2004; 286: G693-G697.
23. Cohen MA, Ellis SM, Le RC, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701.
24. Dixon JB, Pories WJ, O'Brien PE, et al. Surgery as an effective early intervention for diabesity. Diabetes Care 2005; 28: 472-474.
25. Dimick JB, Welch HG, Birkmeyer JD. Surgical mortality as an indicator of hospital quality. JAMA 2004; 292: 847-851.